CytRx (CYTR) Updates on Aldoxorubicin Phase 2 in GBM; Has Now Shown Two Complete Responses
Tweet Send to a Friend
CytRx (NASDAQ: CYTR) announced positive updated results from its ongoing Phase 2 clinical trial with aldoxorubicin for the treatment of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
